Please login to the form below

Not currently logged in
Email:
Password:

Spinraza

This page shows the latest Spinraza news and features for those working in and with pharma, biotech and healthcare.

New data shows benefits for presymptomatic SMA patients treated with Zolgensma

New data shows benefits for presymptomatic SMA patients treated with Zolgensma

Since then, Zolgensma has been in competition with Biogen’s SMA drug Spinraza, approved in 2016, and Roche’s newly approved oral therapy Evrysdi.

Latest news

More from news
Approximately 21 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • #OrkambiNow? #OrkambiNow?

    But Orkambi is not the only orphan disease drug stuck in market access limbo in the England – Biogen’s Spinraza and BioMarin’s Kuvan are both currently suffering similar fates, and

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    only other SMA treatment available, Biogen’s Spinraza. ... The company argues that current ten- year costs of caring for SMA type 1 patients with Spinraza and additional care costs are somewhere between $2.5-$5m.

  • No incentive for a cure No incentive for a cure

    And Spinraza from Biogen, the first ever disease-modifying treatment for spinal muscular atrophy (SMA), which increases the body’s ability to produce SMN protein critical to  the health of motor ... And the lack of affordability - as well as the bad

  • The good, the bad and the ugly The good, the bad and the ugly

    Tecfidera (MS) and Spinraza (Spinal Muscular Atrophy) are expected to generate big sales, while Tysabril (MS and Crohn’s Disease) and Avonex (MS) are expected to see sales drop due to

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    2015 and in the EU 2016) and Spinraza (for the treatment of spinal muscular atrophy, only approved in the US).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • Article: Market access in Brazil

    All eyes on Spinraza. Director Rachel Howard asks, “What does Brazil’s unprecedented risk-sharing agreement in Spinal Muscular Atrophy (SMA) mean for the future of market access in Brazil? ... In April 2019, Brazilian Health Minister Luiz Henrique

  • Research Partnership

    Healthcare under AMLO – One year on. All eyes on Spinraza.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....